ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,833,180 | -4.7% | 329,274 | -9.1% | 0.02% | 0.0% |
| Q2 2023 | $32,341,160 | -12.3% | 362,366 | +1.6% | 0.02% | -17.2% |
| Q1 2023 | $36,891,462 | -12.1% | 356,637 | +3.8% | 0.03% | -14.7% |
| Q4 2022 | $41,975,348 | +18.7% | 343,694 | +0.3% | 0.03% | +9.7% |
| Q3 2022 | $35,377,000 | +11.8% | 342,600 | +0.6% | 0.03% | +19.2% |
| Q2 2022 | $31,651,000 | -23.6% | 340,486 | -3.5% | 0.03% | -7.1% |
| Q1 2022 | $41,410,000 | -4.5% | 352,846 | +9.5% | 0.03% | +3.7% |
| Q4 2021 | $43,345,000 | -1.6% | 322,198 | +16.6% | 0.03% | -10.0% |
| Q3 2021 | $44,045,000 | +28.7% | 276,333 | +6.2% | 0.03% | +30.4% |
| Q2 2021 | $34,216,000 | +33.2% | 260,103 | +30.5% | 0.02% | +21.1% |
| Q1 2021 | $25,697,000 | – | 199,383 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |